文献速递食管胃疾病与幽门螺杆菌

系统综述与Meta分析:伏诺拉生为基础的三联疗法根除幽门螺杆菌的疗效

Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
PubMed 文献 · Aliment Pharmacol Ther · 2017-05-12

该系统综述与Meta分析纳入10项研究共10644例患者,比较伏诺拉生为基础三联疗法与PPI为基础三联疗法根除幽门螺杆菌的疗效。意向性分析显示,伏诺拉生组粗根除率为87.9%,PPI组为72.8%,伏诺拉生组根除率优于PPI组(合并RR=1.19,95%CI 1.15-1.24)。因不良事件退出率及任何不良事件发生率两组均无显著差异。

要点

  • 伏诺拉生为基础三联疗法根除率87.9%,PPI为基础三联疗法为72.8%(意向性分析)。
  • 伏诺拉生组根除率优于PPI组,合并RR=1.19(95%CI 1.15-1.24)。
  • 因不良事件退出率合并RR=0.69(95%CI 0.23-2.03),两组无显著差异。

核心结论

  • 伏诺拉生为基础的三联疗法在幽门螺杆菌根除方面疗效优于PPI为基础的三联疗法。
  • 伏诺拉生为基础的三联疗法耐受性和不良事件发生率与PPI为基础的三联疗法相当。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、EMBASE和Cochrane Library数据库。
  • 纳入评估伏诺拉生为基础与PPI为基础三联疗法根除率的研究,共纳入10项研究、10644例患者。

主要发现

  • 意向性分析粗根除率:伏诺拉生为基础三联疗法为87.9%,PPI为基础三联疗法为72.8%。
  • 伏诺拉生为基础三联疗法根除率优于PPI为基础三联疗法,合并RR=1.19(95%CI 1.15-1.24)。
  • 因不良事件退出率两组无显著差异,合并RR=0.69(95%CI 0.23-2.03)。
  • 任何不良事件发生率两组无显著差异,合并RR=1.02(95%CI 0.78-1.34)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In order to increase eradication rates, vonoprazan, a novel potassium-competitive acid blocker, has been used in Helicobacter pylori eradication therapy. AIM: To summarise the results of the efficacy of vonoprazan-based triple therapy, helping clinicians to better understand the benefit of vonoprazan in the treatment of H. pylori infection. METHODS: We conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords "vonoprazan," "takecab", "TAK-438," "potassium," "competitive," "potassium-competitive," "Helicobacter," and "pylori." Studies were included if they evaluated the eradication rate between the vonoprazan-based and proton pump inhibitor (PPI)-based triple therapies. RESULTS: Ten studies and 10 644 patients were evaluated. The crude H. pylori eradication rate determined by intention-to-treat analysis was 87.9% and 72.8% in the vonoprazan-based triple therapy and PPI-based triple therapy respectively. The eradication rate of the vonoprazan-based triple therapy was superior to that of the PPI-based triple therapy (pooled risk ratio [RR] [95% confidence interval (CI)]=1.19 [1.15-1.24]) In addition, there was no significant difference in dropout rate due to adverse event between the regimens (pooled RR of the vonoprazan-based triple therapy [95% CI]=0.69 [0.23-2.03]). The incidence of any adverse events also did not differ between the regimens (pooled RR [95% CI]=1.02 [0.78-1.34]). CONCLUSIONS: The vonoprazan-based triple therapy showed superior efficacy in terms of H. pylori eradication as compared to the PPI-based triple therapy. In addition, the vonoprazan-based triple therapy showed comparable tolerability and incidence of adverse events.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jung YS, Kim EH, Park CH, et al. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017. PMID: 28497487. doi:10.1111/apt.14130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。